Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Arcus Biosciences by Year
Arcus Biosciences — Total liabilities (legacy XBRL tag, $M) ($M)
Gilead Sciences Arcus Biosciences: $751M in FY2021, up 178.0% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2021
751
Period ended Dec 31, 2021
Change on a year earlier
+178.0%
270 in FY2020
History
3 years
Since FY2019
Sources
3
Documents cited below
Where the FY2021 figure comes from
Source: SEC Filing ↗
Reported in Arcus Biosciences (RCUS) Form 10-Q / 10-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arcus Biosciences — Total liabilities (legacy XBRL tag, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 751 | +178.0% | SEC Filing ↗ |
| FY2020 | Dec 31, 2020 | 270 | +587.0% | SEC Filing ↗ |
| FY2019 | Dec 31, 2019 | 39.3 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Gilead Sciences Arcus Biosciences ($M), annual FY2019–FY2021 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus-liab-tot
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.